Related references
Note: Only part of the references are listed.Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Mangeng Cheng et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C. Lee et al.
BIOCHEMICAL JOURNAL (2010)
Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
Roberto T. Bossi et al.
BIOCHEMISTRY (2010)
Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase
Karen L. Milkiewicz et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
ALK fusion genes in children with atypical myeloproliferative leukemia
S. Roettgers et al.
LEUKEMIA (2010)
Anaplastic lymphoma kinase: signalling in development and disease
Ruth H. Palmer et al.
BIOCHEMICAL JOURNAL (2009)
Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: Elimination of an acid-mediated decomposition pathway
Stanley D. Chamberlain et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity
Stanley D. Chamberlain et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase
Stanley D. Chamberlain et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Inhibition of ALK Signaling for Cancer Therapy
Yael P. Mosse et al.
CLINICAL CANCER RESEARCH (2009)
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
Thomas R. Webb et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Anaplastic lymphoma kinase: an oncogene for tumor vaccination
Cristina Mastini et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
Eva Lin et al.
MOLECULAR CANCER RESEARCH (2009)
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
Peter Sabbatini et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer
Hiroyuki Mano
CANCER SCIENCE (2008)
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoro-propyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity
Upender Velaparthi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Roberto Chiarle et al.
NATURE MEDICINE (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V. Galkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase
RS Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Discovery of a 1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity
M Wittman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Share Paper
